Wedge Capital Management’s Royalty Pharma RPRX Stock Holding History

Wedge Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.2M	Sell	770,422 -120,418	-14%	-$6.27M	0.71%	28
2026 Q1	$42.7M	Sell	890,840 -149,128	-14%	-$6.53M	0.79%	29
2025 Q4	$40.2M	Sell	1,039,968 -152,473	-13%	-$5.81M	0.72%	30
2025 Q3	$42.1M	Sell	1,192,441 -22,480	-2%	-$814K	0.71%	30
2025 Q2	$43.8M	Buy	1,214,921 +200,122	+20%	+$6.63M	0.78%	28
2025 Q1	$31.6M	Buy	+1,014,799	New	+$32.2M	0.61%	80

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedge Capital Management's RPRX Position: Q2 2026 in Review

Wedge Capital Management reduced its Royalty Pharma (RPRX) stake by 14% in Q2 2026, selling an estimated $6.27M and leaving 770,422 shares worth $43.2M. The position accounts for 0.71% of the portfolio, ranked #28.

Wedge Capital Management first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $43.8M in Q2 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Wedge Capital Management held 770,422 shares of Royalty Pharma worth $43.2M as of Q2 2026.
Wedge Capital Management sold 120,418 Royalty Pharma shares in Q2 2026, an estimated $6.27M.
Royalty Pharma made up 0.71% of Wedge Capital Management's portfolio in Q2 2026, its #28 holding.
Wedge Capital Management first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
Wedge Capital Management's Royalty Pharma position peaked at $43.8M in Q2 2025.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.